Arbutus生物製藥 ABUS 深 滬
已收盤 02-06 16:00:00 美东时间
3.84
+0.170
+4.63%
華盛通- 最 高3.90
- 今 開3.84
- 成交量 256.25万股
- 最 低 3.67
- 昨 收 3.67
- 總市值 7.39亿
- 52周最高 5.10
- 市盈率 靜 --
- 換手率 1.33%
- 52周最低 2.705
- 委 比 99.10%
- 總股本 1.92亿
- 歷史最高 31.48
- 量 比 1.05
- 振 幅 6.27%
- 歷史最低 0.821
- 每 手 1
- 風險率 0.58%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Arbutus falls as patent dispute with Moderna hits EU snag
Arbutus Biopharma (ABUS) lost ~14% in the premarket on Friday after the company disclosed that the Board of Appeal of the European Patent Office revoked one of its patents, which was the subject of a ...
01-16 21:41
Arbutus Biopharma Faces EPO Revocation in Moderna Dispute
Arbutus Biopharma ( ($ABUS) ) has issued an update. On January 15, 2026, the Eu...
01-16 20:57
Arbutus Biopharma CEO Discusses Lawsuits Over LNP Technology
Arbutus Biopharma ( ($ABUS) ) has issued an announcement. On December 11, 2025,...
2025-12-11 21:29
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
2025-11-17 10:49
Chardan Capital Maintains Buy on Arbutus Biopharma, Maintains $5 Price Target
Chardan Capital analyst Keay Nakae maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $5 price target.
2025-11-15 04:56
Arbutus Biopharma Q3 EPS $(0.04) Misses $(0.03) Estimate, Sales $529.000K Miss $1.267M Estimate
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.03) by 33.33 percent. This is a 60 percent increase over losses of $(0.10) per share from
2025-11-13 20:31
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
Arbutus Biopharma announced that four abstracts, including imdusiran and AB-101 data, were accepted for poster presentations at AASLD 2025. Notably, the AB-101 abstract was selected as a Poster of Distinction. The studies highlight imdusiran's safety, tolerability, and potential to enhance immune responses in chronic hepatitis B patients, while AB-101 showed promising safety and efficacy as a PD-L1 inhibitor. These findings underscore progress to...
2025-10-07 12:00
Arbutus Biopharma’s Patent Ruling in Pfizer Lawsuit
The latest update is out from Arbutus Biopharma ( ($ABUS) ). On September 9, 20...
2025-09-10 21:30
Chardan Capital Maintains Buy on Arbutus Biopharma, Maintains $5 Price Target
Chardan Capital analyst Keay Nakae maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $5 price target.
2025-08-11 19:22
